Comparison of Two Doses of Enoxaparin for Thromboprophylaxis in Hospitalized COVID-19 Patients

• Status: Completed
• Trial end date: 2021-05-25
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine whether a higher dose of low molecular weight heparin (enoxaparin 40 mg b.i.d.) is superior than the standard prophylaxis dose (enoxaparin 40 mg o.d.) in reducing thromboembolic events in COVID-19 patients.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Niguarda Hospital
• Treatments: Enoxaparin

Criteria

Inclusion Criteria:

• All-comers patients aged >=18 years and admitted to hospital with laboratory-confirmed SARS-CoV-2 infection

Exclusion Criteria:

• Patients admitted directly to an intensive care unit;

• Estimated creatinine clearance <15 ml/min/1.73m2;

• Patients needing anticoagulant for prior indication;

• Participants involved in other clinical trials;

• Any other significant disease or disorder which, in the opinion of the investigator, may either put the participants at risk because of participation in the trial, or may influence the result of the trial, or the participant's ability to participate in the trial.